New Genetic Target May Hold Promise in Treating Blindness
The SARM1 gene is a key driver in the damage that ultimately leads to impaired vision.
This content originally appeared on our sister site, Ophthalmology Times.
Scientists from Trinity College Dublin have identified a target with great promise for treating a number of genetic forms of blindness.
The gene they identified, SARM1, is a key driver in the damage that ultimately leads to impaired vision (and sometimes blindness), and—in a disease model—showed that deleting this gene protects vision after a chemical kick-starts the chain of dysfunction that mimics a host of ocular conditions.
According to a release from Trinity College Dublin, this means that therapies targeting suppression of SARM1 activity may hold the key to effective new options for treating a suite of diseases that can have a devastating impact on quality of life, and for many of which there are no treatment options currently available.
The scientists, led by a team from Trinity’s School of Genetics and Microbiology, recently published their findings in the International Journal of Molecular Sciences.
READ MORE: Gene Therapy for Diabetic Retinopathy Yields Continued Improvements
According to lead author Laura Finnegan, a PhD candidate at Trinity, in response to injury SARM1 contributes to a process that leads to the degeneration of specialized cells and their axons in the eye.
“When this happens it essentially means that the optic nerve can no longer deliver signals from the eye to the brain,” she said in the release. “Impaired vision and blindness is extremely debilitating for millions of people across the globe, which is one of the main motivations for us to seek to better understand the genetic causes and, potentially, develop life-changing therapies.”
Moreover, Jane Farrar, a professor in Trinity’s School of Genetics and Microbiology and a senior author on the paper, noted in the release that another key finding was that visual function was still preserved when reassessed four months after SARM1 was deleted, indicating that the benefits can remain over time.
“This raises hopes that a targeted therapy delivered early enough may offer people diagnosed with an ocular neuropathy long-lasting preservation of sight,” Farrar said in the release. “We have a way to go before such a therapy is available but this work represents a significant step, sheds light on the pathway forward and offers hope that a range of diseases involving the optic nerve—from maternally inherited conditions such as Leber Hereditary Optic Neuropathy to the more commonly known glaucoma—will one day be treatable via such therapies.”
The research is the result of collaboration between Professor Farrar’s lab in the School of Genetics and Microbiology and that of Professor Andrew Bowie’s in the School of Biochemistry and Immunology in the Trinity Biomedical Sciences Institute.
It was funded by the Irish Research Council, Science Foundation Ireland, the Health Research Board of Ireland and Fighting Blindness Ireland.
